DOC

Key Points to Review Before Investing in DOC Stock

Shares of Healthpeak Properties have moved -1.2% today, and are now trading at a price of $19.29. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 2,958,068 compared to the stock's average volume of 5,389,015.

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Based in Denver, United States the company has 193 full time employees and a market cap of $13,575,955,456. Healthpeak Properties currently offers its equity investors a dividend that yields 6.1% per year.

The company is now trading -12.6% away from its average analyst target price of $22.07 per share. The 14 analysts following the stock have set target prices ranging from $19.0 to $25.0, and on average give Healthpeak Properties a rating of buy.

Over the last 12 months DOC shares have declined by -7.0%, which represents a difference of -30.3% when compared to the S&P 500. The stock's 52 week high is $22.38 per share and its 52 week low is $15.24. With its net margins declining an average -8.8% over the last 6 years, Healthpeak Properties declining profitability gives us reason to believe its stock price will continue to underwhelm.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 543,463 43,767 8 -61.9
2022 526,635 110,036 21 10.53
2021 457,699 86,783 19 18.75
2020 437,505 68,488 16 -15.79
2019 415,281 77,186 19 35.71
2018 422,551 58,321 14
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS